You are here

Novel Focal Adhesion Kinase autophosphorylation inhibitors against pancreatic cancer

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA188978-01A1
Agency Tracking Number: R41CA188978
Amount: $219,534.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCI
Solicitation Number: PA14-072
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
ORCHARD PARK, NY 14127-3049
United States
DUNS: 961691875
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (716) 845-3920
Business Contact
Phone: (716) 525-3985
Research Institution
*(FY99 USE 3934901)
BUFFALO, NY 14263-
United States

 () -
 Domestic nonprofit research organization

DESCRIPTION (provided by applicant): Due to the absence of effective therapies, pancreatic cancer is the fourth leading cause of cancer deaths in both men and women. This study focuses on the development of new small molecule inhibitors targeting Focal Adhesion Kinase against pancreatic cancer. Focal Adhesion Kinase (FAK) has been shown to play an important role in tumor cell survival, including pancreatic cancer, making FAK an excellent target for anti- cancer therapy. Recently, a novel small molecule autophosphorylation FAK inhibitor (1,2,4,5- Benzenetetraamine tetrahydrochloride) called Y15 has been developed by our group that directly and specifically decreased FAK autophosphorylation in vitro and significantly inhibited pancreatic tumor growth in vivo.Y15 inhibitor has a novel mechanism of action; its advantage over existing therapeutic approaches is that that it targets the autophosphorylation site (Y397) of FAK. Y15 is highly specific and non-toxic. The objective of the proposal is to synthesize

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government